| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US11590081 | TRIS PHARMA INC | NA |
Sep, 2038
(14 years from now) | |
Dyanavel Xr 10 is owned by Tris Pharma Inc.
Dyanavel Xr 10 contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.
Dyanavel Xr 10 has a total of 4 drug patents out of which 0 drug patents have expired.
Dyanavel Xr 10 was authorised for market use on 04 November, 2021.
Dyanavel Xr 10 is available in tablet, extended release;oral dosage forms.
Dyanavel Xr 10 can be used as method of treating attention deficit hyperactivity disorder.
The generics of Dyanavel Xr 10 are possible to be released after 24 September, 2038.
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 10 family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic